Literature DB >> 31296562

Functional divergence caused by mutations in an energetic hotspot in ERK2.

Clinton A Taylor1, Kevin W Cormier1, Shannon E Keenan2, Svetlana Earnest1, Steve Stippec1, Chonlarat Wichaidit1, Yu-Chi Juang1, Junmei Wang3, Stanislav Y Shvartsman2, Elizabeth J Goldsmith3, Melanie H Cobb4.   

Abstract

The most frequent extracellular signal-regulated kinase 2 (ERK2) mutation occurring in cancers is E322K (E-K). ERK2 E-K reverses a buried charge in the ERK2 common docking (CD) site, a region that binds activators, inhibitors, and substrates. Little is known about the cellular consequences associated with this mutation, other than apparent increases in tumor resistance to pathway inhibitors. ERK2 E-K, like the mutation of the preceding aspartate (ERK2 D321N [D-N]) known as the sevenmaker mutation, causes increased activity in cells and evades inactivation by dual-specificity phosphatases. As opposed to findings in cancer cells, in developmental assays in Drosophila, only ERK2 D-N displays a significant gain of function, revealing mutation-specific phenotypes. The crystal structure of ERK2 D-N is indistinguishable from that of wild-type protein, yet this mutant displays increased thermal stability. In contrast, the crystal structure of ERK2 E-K reveals profound structural changes, including disorder in the CD site and exposure of the activation loop phosphorylation sites, which likely account for the decreased thermal stability of the protein. These contiguous mutations in the CD site of ERK2 are both required for docking interactions but lead to unpredictably different functional outcomes. Our results suggest that the CD site is in an energetically strained configuration, and this helps drive conformational changes at distal sites on ERK2 during docking interactions.

Entities:  

Keywords:  ERK CD site; kinase; mutation; stability

Year:  2019        PMID: 31296562      PMCID: PMC6681740          DOI: 10.1073/pnas.1905015116

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  60 in total

1.  Identification of novel MAP kinase pathway signaling targets by functional proteomics and mass spectrometry.

Authors:  T S Lewis; J B Hunt; L D Aveline; K R Jonscher; D F Louie; J M Yeh; T S Nahreini; K A Resing; N G Ahn
Journal:  Mol Cell       Date:  2000-12       Impact factor: 17.970

2.  A conserved docking motif in MAP kinases common to substrates, activators and regulators.

Authors:  T Tanoue; M Adachi; T Moriguchi; E Nishida
Journal:  Nat Cell Biol       Date:  2000-02       Impact factor: 28.824

3.  Crystal structures of MAP kinase p38 complexed to the docking sites on its nuclear substrate MEF2A and activator MKK3b.

Authors:  Chung I Chang; Bing-e Xu; Radha Akella; Melanie H Cobb; Elizabeth J Goldsmith
Journal:  Mol Cell       Date:  2002-06       Impact factor: 17.970

4.  MOLPROBITY: structure validation and all-atom contact analysis for nucleic acids and their complexes.

Authors:  Ian W Davis; Laura Weston Murray; Jane S Richardson; David C Richardson
Journal:  Nucleic Acids Res       Date:  2004-07-01       Impact factor: 16.971

5.  Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.

Authors:  Paul T C Wan; Mathew J Garnett; S Mark Roe; Sharlene Lee; Dan Niculescu-Duvaz; Valerie M Good; C Michael Jones; Christopher J Marshall; Caroline J Springer; David Barford; Richard Marais
Journal:  Cell       Date:  2004-03-19       Impact factor: 41.582

6.  Coot: model-building tools for molecular graphics.

Authors:  Paul Emsley; Kevin Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-11-26

7.  Likelihood-enhanced fast translation functions.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Laurent C Storoni; Randy J Read
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2005-03-24

8.  Identification of novel point mutations in ERK2 that selectively disrupt binding to MEK1.

Authors:  Fred L Robinson; Angelique W Whitehurst; Malavika Raman; Melanie H Cobb
Journal:  J Biol Chem       Date:  2002-01-31       Impact factor: 5.157

9.  Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125.

Authors:  Yong-Seok Heo; Su-Kyoung Kim; Chang Il Seo; Young Kwan Kim; Byung-Je Sung; Hye Shin Lee; Jae Il Lee; Sam-Yong Park; Jin Hwan Kim; Kwang Yeon Hwang; Young-Lan Hyun; Young Ho Jeon; Seonggu Ro; Joong Myung Cho; Tae Gyu Lee; Chul-Hak Yang
Journal:  EMBO J       Date:  2004-05-13       Impact factor: 11.598

10.  Docking motif interactions in MAP kinases revealed by hydrogen exchange mass spectrometry.

Authors:  Thomas Lee; Andrew N Hoofnagle; Yukihito Kabuyama; James Stroud; Xiaoshan Min; Elizabeth J Goldsmith; Lin Chen; Katheryn A Resing; Natalie G Ahn
Journal:  Mol Cell       Date:  2004-04-09       Impact factor: 17.970

View more
  5 in total

1.  Inference of Multisite Phosphorylation Rate Constants and Their Modulation by Pathogenic Mutations.

Authors:  Eyan Yeung; Sarah McFann; Lewis Marsh; Emilie Dufresne; Sarah Filippi; Heather A Harrington; Stanislav Y Shvartsman; Martin Wühr
Journal:  Curr Biol       Date:  2020-02-13       Impact factor: 10.834

Review 2.  Development of small molecule extracellular signal-regulated kinases (ERKs) inhibitors for cancer therapy.

Authors:  Xiaoli Pan; Junping Pei; Aoxue Wang; Wen Shuai; Lu Feng; Faqian Bu; Yumeng Zhu; Lan Zhang; Guan Wang; Liang Ouyang
Journal:  Acta Pharm Sin B       Date:  2022-01-04       Impact factor: 14.903

Review 3.  Mutations That Confer Drug-Resistance, Oncogenicity and Intrinsic Activity on the ERK MAP Kinases-Current State of the Art.

Authors:  Karina Smorodinsky-Atias; Nadine Soudah; David Engelberg
Journal:  Cells       Date:  2020-01-06       Impact factor: 6.600

4.  Non-Canonical Caspase Activity Antagonizes p38 MAPK Stress-Priming Function to Support Development.

Authors:  Benjamin P Weaver; Yi M Weaver; Shizue Omi; Wang Yuan; Jonathan J Ewbank; Min Han
Journal:  Dev Cell       Date:  2020-04-16       Impact factor: 12.270

5.  Interference with ERK-dimerization at the nucleocytosolic interface targets pathological ERK1/2 signaling without cardiotoxic side-effects.

Authors:  Angela Tomasovic; Theresa Brand; Constanze Schanbacher; Sofia Kramer; Martin W Hümmert; Patricio Godoy; Wolfgang Schmidt-Heck; Peter Nordbeck; Jonas Ludwig; Susanne Homann; Armin Wiegering; Timur Shaykhutdinov; Christoph Kratz; Ruth Knüchel; Hans-Konrad Müller-Hermelink; Andreas Rosenwald; Norbert Frey; Jutta Eichler; Dobromir Dobrev; Ali El-Armouche; Jan G Hengstler; Oliver J Müller; Karsten Hinrichs; Friederike Cuello; Alma Zernecke; Kristina Lorenz
Journal:  Nat Commun       Date:  2020-04-07       Impact factor: 14.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.